This review highlights the invaluable contribution of in-vivo rodent models in dissecting the underlying neurobiology for numerous neurodevelopmental disorders. Currently, models are routinely generated with precision genomics and characterized for research on neurodevelopmental disorders. In order to impact translation, outcome measures that are translationally relevant are essential. This review emphasizes the importance of accurate neurobehavioral and anatomical analyses.
INTRODUCTION
Neurodevelopmental disorders (NDDs) are a broad, diverse group of neurobehavioral disorders defined by significant impairments in one or more domains of functioning (e.g. social interactions, cognition, language, motor behaviors). NDDs are prevalent and pervasive lifelong conditions. Deficits can include delays in achieving outcomes and impaired skills or the presence of atypical behaviors. Although cures (e.g. gene therapy) are not imminent, recent innovations in delivery methods associated with gene products and targeted pharmaceuticals, whenever combined with evidence-based behavioral interventions, have reinvigorated basic and clinical research.
The diagnostic criteria for NDDs, outlined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM5), are a group of neurodevelopmental disorders of unknown albeit numerous causes with no biological markers. Thus, a diagnosis is defined exclusively by behavioral criteria in the distinct domains. The most classic example is intellectual disability, which is diagnosed by deficits in both cognitive and adaptive functioning relative to peers of the same age, sex and socioeconomic group. In addition to the features essential to a diagnosis of intellectual disability, challenging behaviors are frequently observed, often resulting from limitations in communicative and behavioral regulation abilities. Although the presence of challenging behaviors are not a part of the intellectual disability diagnosis, these behavioral deficits may impede the process of the appropriate diagnosis and course of intervention [1] .
Autism spectrum disorder (ASD) is another prominent NDD diagnosed by persistent impairments in reciprocal social interaction and deficits in social communication across multiple contexts and repetitive behaviors, with highly fixated, restricted interests and behavioral inflexibility. DSM5 diagnoses include a broader definition of the ASD phenotype than earlier versions to better reflect the current consensus that the causes and clinical presentations of ASD are highly heterogeneous. ASD and Attention-Deficit/Hyperactivity Disorder (ADHD) are frequently co-occurring [2] [3] [4] . ADHD is characterized by persistent problems in attention and/or excessive motor restlessness and/or impulsivity that significantly interfere with functioning [5] . Impulsivity also refers to a lack of reflection in the decision-making process.
Other NDDs fall into classes of communication or motor disorders, both of which are also heterogeneous. Communication disorders are diagnosed by one or more deficiencies in a wide variety of subdomains such as competence in phonology, morphology, syntax and pragmatics and may adversely affect any or all of these subdomains. Motor disorders are defined by significant delays to reach developmental motor milestones and/or persistent and unusual patterns of typical motor abilities that cause detrimental impact [5, 6] .
CUTTING-EDGE GENETICS FAST FORWARDS TRANSLATIONAL SCIENCE
Stratifying patient phenotypic subgroups and focusing on genetically identifiable populations of individuals with NDDs is a main focus of neurological research. With the advent of next-generation sequencing techniques, numerous genetic factors have been shown to confer risk for ASD and intellectual disability , with more than 100 genes implicated in syndromic ASD cases [7] [8] [9] [10] [11] and over 700 genes identified across studies of X-linked, autosomal-dominant and autosomal-recessive intellectual disability, which can be used for the molecular diagnosis of intellectual disability and ASD [12,13,14 & ]. Recently, whole exome and targeted sequencing approaches have further clarified the role of 49 different genes as greater than mere 'candidate ASD genes,' but mid-to high-confidence genes [7, [15] [16] [17] . This past year, eight novel precision medicine-driven mouse models with mutations in two of the highest confidence genes, chromatin helicase domain 8 (Chd8) and AT-rich interactive domain 1B (Arid1b) debuted for behavioral, cellular, anatomical and molecular characterization studies [18, 19 && ,20-25]. As our knowledge of genes involved in NDDs, in particular ASD and intellectual disability, expands and the number of genes we identify increases, common pathways are emerging. Mechanistically, gene products of de novo mutations show strong enrichment for chromatin modifiers and transcriptional regulators (e.g. CHD8, ARID1B), embryonically expressed genes (e.g. TBR1, DYRK1A, PTEN), cellular signaling pathway components (MAPK and Rho-GTPase) and molecules that are highly expressed in the postsynaptic density (e.g. GRIN2B, GABRB3, SHANK3). Networks constructed using these high-confidence risk genes reveal converging functional pathways in ASD and intellectual disability [11, 14 & ,26
BEHAVIORAL APPROACHES IN PRECLINICAL MOUSE MODELS
Basic research into the above common underlying mechanisms of disease to develop targeted treatment options first requires well controlled in vivo studies in model organisms with a high degree of genetic conservation relative to humans. To date, the most useful models with high construct validity have been mouse models [28, 29] . Although forging definitive links between genetic alterations and complex behavioral impairments (i.e. face validity)
KEY POINTS
Next generation technology has generated an abundance of precise novel genetic mouse models that are essential for research on neurodevelopmental disorders (NDDs).
Translational outcome measures, such as behavior and brain anatomy, are leading numerous discoveries of the underlying NDD neurobiology via the new mouse models.
Behavioral domains core to NDD are complex and require multiple assays for accurate interpretation.
Linking behavioral outcomes with neuroanatomical metrics will inform mechanistic hypotheses and therapeutic targets.
Systems level approaches will be heavily relied upon for therapeutic development, as biological markers and outcome measures. [38] , jumping [39] [40] [41] , back flipping [42, 43] and/or overall hyperactivity [44] [45] [46] in a broad variety of preclinical models. Insistence on sameness and lack of cognitive flexibility in NDDs has been modeled in several rodent models using a few different assays [47, 48] . In the following, we highlight the breadth of examinations currently available in one behavioral domain, social behavior, that are utilized for identifying face validity (deficits in social communication) in construct valid genetic models.
TOWARD BENEFICIAL AND COMPREHENSIVE SOCIAL PHENOTYPING
Three-chambered approach is an automated and widely used assay that compares time that the subject mouse spends with a novel mouse versus time spent with a nonsocial inanimate object [49] . A more fine-grained level of detail is collected during the naturalistic reciprocal dyad interactions, where two unfamiliar subject mice are placed together in a clean, empty test arena.
Interactions are usually examined between sexand age-matched juveniles and quantified parameters are measured using the rich history from the established literature [35, 50, 51] . These dyad interactions can also be quantified during male-female social interactions. USV calls, emitted by the sexually motivated male, can also be assessed during these tasks to provide two outcome measures of sociability. USV are also emitted by rodent pups whenever separated from their mothers and littermates and reductions in number of neonatal USV emissions have been reported in numerous ASD mouse models [35, [52] [53] [54] [55] . Social recognition involves social memory and is commonly examined in rodents through a few different procedures that utilize the innate preference of adult rodents to spend more time with novel over familiar conspecifics. Dysregulation of the oxytocin system has been shown to be relevant for this component of social behavior [56] [57] [58] [59] [60] . Social conditioned place preference measures a component of social behavior alongside motivational components. Social place preference arenas pair one of two unique contexts with social interactions for a fixed number of conditioning sessions, during which wildtype control mice develop a place preference to the context associated with social interactions. Given the diversity of social behaviors (e.g. parental investment, mating, cooperation), this task is modifiable to measure motivation for subtypes of social reward and social behavior in models of NDDs [61] . However, one significant challenge to preclinical assays that quantify social behavior is the inability to lesion a brain region and eliminate all social behavior or pharmacologically validate and manipulate the behavior with positive control compounds, as behavioral scientists have been able to do with other sophisticated behaviors (e.g. anxiety and benzodiazepines).
Social deficits in genetic mouse models of ASD across mechanisms of action have been reported but with an inconsistency of findings. Deficits in the social behavioral domain have been mild in some cases [62] or in other cases did not fully recapitulate across laboratory environments [63] [64] [65] [66] [67] . For a core pillar behavioral domain in ASD diagnosis, this reemphasizes the need to conduct comprehensive, meticulous and more fine-grained analyses of complex behavioral tasks. Opportunities for the improvement of preclinical research in social behavior include applauding reports that fail to find a social deficit in a genetic mouse model of ASD. In the long run, the NDD field would benefit from this cautionary approach before labeling a new mouse tool an 'autism mouse' based on a mere single of these subtype(s) of behavioral findings that has not been reproduced either intra-or interlaboratory environments.
Key points from our laboratories, which have been successful with reproducibility, include a recommendation of using a minimum of two assays in each behavioral domain before making strong conclusions on social or cognitive behavioral phenotypes [32] . This point is especially salient for the social behavioral domain. Sociability is sophisticated and nuanced, much like complex executive learning functions. Moreover, there are numerous components of social behavior for a wide variety of functional outcomes including motivation, learning, dominance, thriving, maternal behavior and sex. Second, and importantly, is that methods employed for behavioral phenotyping of clinically relevant traits are riddled with nuance and should be conducted exclusively by trained technicians with demonstrated proficiency. Finally, to have the utmost translational value, behavioral phenotyping assays should be blinded, unbiased, and highly powered and utilize appropriate age-matched, littermate controls, in both males and females (n ¼ 15-20 per genotype/sex for two independent cohorts) to assess behavioral abnormalities, analogous to observed in clinical populations. Other relevant biological variables such as breeding scheme, genetic background, enrichment in home cages and circadian rhythm/time of day should be carefully controlled, adequately considered and described in severe detail in the methods text. The importance of procedural and environmental differences often complicate direct comparisons of phenotypic data; however, these points are not insurmountable [68, 69] 
INNOVATIVE OUTCOME MEASURES FOR COGNITION IN NEURODEVELOPMENTAL DISORDERS
Until recently, cognitive tests for measuring learning and memory in animal models were underdeveloped in complexity, and with most commonly used tests relying on rudimentary stimuli and procedures. Most learning tasks are simplistic mazes and/or footshock-based paradigms. This uncritical use of behavioral paradigms may account for the low predictability of mouse models in psychiatric disorders. Newer assays of cognitive abilities for ASD, intellectual disability and ADHD include computerized assessments of simple learning, higher order cognitive flexibility and attention and impulsivity, which are more ideal because they are automated and avoid investigator interference that can have enormous influence on behavioral effects. Automation in preclinical assays is also more analogous to increasingly automated clinical testing for NDDs (e.g. NIH toolbox), and is able to measure multiple domains of cognitive ability and build upon previously learned rules. Automated touchscreen technology has been employed for tasks of visual discrimination and reversal to identify affected circuits in models with genetic mutations associated with ASD and intellectual disability [33 
CONSIDERATIONS FOR COMPLEX BEHAVIORAL PHENOTYPES
For many of these complex behavioral assays outlined above, the ultimate goal is to identify disease-relevant endpoints that are robust, reliable and reproducible, and that can be employed to evaluate potential novel therapeutic agents. The impact of a competing or confounding behavior on the behavioral endpoints listed above cannot be understated. For example, mutations can cause physical impairments that limit ability to perform a task. Genetic mutations relevant to ASD and intellectual disability that caused physical defects (e.g. smaller body weights) include the most common copy number variant in ASD, 16p11.2 deletions [38] . Motor defects in ASD models including hypolocomotion [33 & ,34] and hyperlocomotion [44] [45] [46] [73] [74] [75] can also have consequences on the behavioral outcome of interest by competing or preventing the subject from engaging in the tasks for testing core symptomology. Just as it is important to understand the limitations of a behavioral task itself, it is important to investigate, acknowledge, and report the limitations of the rodent model being tested so as not to be shortsighted in the interpretations and applications of the data.
NEUROANATOMICAL APPROACHES IN PRECLINICAL MODEL SYSTEMS
In conjunction to behaviorally relevant outcome measures, the search for biomarkers of NDDs has grown and heavily relied upon visualizing the brain in an effort to understand the neurodevelopmental differences in preclinical genetic models and to determine if those neuroanatomical alterations can be reversed or corrected [76, 77] . Neuroanatomical indices of disease in preclinical models of NDDs have successfully identified phenotypes with cellular resolution, using techniques such as histology [78, 79] , two photon microscopy [77] and electron microscopy [80] . Mesoscopic resolution can be obtained with computed tomography (CT) [81, 82] , PET [83] , and MRI [84, 85] . Although the benefits of examining the brain at the cellular resolution are self-evident, such as visualization of processes and/or counting of cell numbers, the lack of whole brain coverage often makes these techniques less than idyllic for NDDs, for which the behavior dysfunction is unlikely to be the result of a single localized brain region, highlighted by numerous clinical imaging studies in ASD, Fragile X and Prader-Willi syndromes [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] .
MRI-FOCUSED NEUROANATOMICAL PHENOTYPING
The ability of MRI-based techniques to encompass multiple brain regions and circuits in a single study is highly advantageous to illustrate causal insults resulting from genetic mutations in a developed, living system. This comprehensive level of whole brain data collection provides a unique opportunity for neurodevelopmental research. Moreover, once methodologies are in place and optimized, MRI provides large datasets with efficiency, throughput and sensitivity [96, 97] . Over the past decade, our collaborative laboratories have shown that most mouse models exhibiting behavioral phenotypes also have prominent detectable neuroanatomical phenotypes [38, 55, [98] [99] [100] . The noninvasive nature of MRI also means that it can be performed repeatedly to track disease progression and loss of skills and/or symptom onset (or regression by reversals of brain phenotypes), extremely beneficial to neurodevelopmental research [101] . A broad variety of imaging sequences can be used to look at differential components of neurodevelopment. For example, diffusion tensor imaging (DTI) infers differences in the tissue microstructure throughout the brain and is extremely sensitive to differences in the white matter [102] .
Preclinical studies using unbiased MRI in mouse models of NDDs have allowed for rapid whole brain phenotyping that alludes to future mechanistic hypothesis-focused research with the aforementioned cellular resolution techniques. Because of this necessity in the genetic mouse model field, MRI assessments of the brain in NDDs have become a staple of the diagnostic battery used to comprehensively phenotype novel mouse models of NDDs.
With over 700 genes implicated in NDDs and greater than 250 mouse models generated to study ASD alone [103, 104] , the demand is pronounced for high-throughput, quality, consistent, optimized and informative MRI scans. Our laboratory group at the Mouse Imaging Centre (MICe) has pioneered this advanced platform of mouse imaging and developed techniques to scan up to 16 mice in a single MRI session [84, 85] , which has helped to maintain and scan the consistent stream of NDD relevant mouse models. Additional improvements to MRI systems such as higher fields or cryogen-cooled coils will help to enhance both the image quality and throughput even further in the near future [76] .
Moving forward the most relevant and informative studies are going to be multimodal combinations of several techniques including genomic analysis, behavioral phenotyping, global physiological outputs and neuroanatomical imaging.
MULTIMODAL PHENOTYPING IN NEXT GENERATION GENETIC MOUSE MODELS
Advances in next generation genomic technology have greatly improved diagnostic capabilities for NDDs and have discovered consistent mutations across the heterogeneity, vigorously contributing to the growing preclinical models of NDDs pool. These studies have identified genes that regulate large gene networks, which end up regulating and affecting numerous postulated mechanisms of action including synaptic development, neuronal function, modulation of transcription process, chromatin remodeling, calcium signaling and cellular signaling pathways. One example from whole exome sequences clarified the role of the chromodomain helicase DNA binding protein-8 (CHD8), with over 15 various mutations in this single gene confirmed to contribute to ASD [105] [106] [107] [108] . Now, as the genetic models become available, the pathway is set for a focused effort to comprehensively define the anatomical phenotype in an unbiased, hypothesis-generating effort that will contrast and compare differences across these models [97] . In collaboration with prominent behavioral scientists, we have spearheaded an effort to correlate neuroanatomical differences with behavioral metrics, which allows for powerful inferences and biochemical hypotheses to be pursued for any given study. In fact, showing direct relationships and links amongst behavior and any of our numerous MRI readouts (e.g. regional volume, DTI, cortical thickness) can be used as biological markers, and outcome measures and may define targets for genetic or pharmacologic intervention.
Recently, we jointly applied behavioral and neuroanatomical phenotyping on the Chd8þ/del5 model of CHD8 mutation in ASD. We observed global macrocephaly, cognitive behavioral deficits, cortical cytoarchitecture anomalies and atypical neurogenesis. Cognitive behavioral deficits were observed in two standard assays of learning and memory, the novel object recognition task and contextual fear conditioning. As the behavioral and structural MRI analyses were performed in the same subject cohort, detected increases in absolute volume of the cortex, hippocampus and amygdala were correlated with deficits (i.e. reduced freezing) in fear conditioning [19 && ]. These additional correlations provide two complimentary outcome measures, which are desperately in demand for pharmaceutical development in NDDs. Other advantages of cross model phenotyping are to highlight brain regions or behavioral domains of interest and decipher previously unknown underlying neural networks. Our efforts of combining behavior with neuroanatomy will aid stratification efforts for NDDs, which will ultimately lead to an increased diagnostic specificity and streamlined therapeutic development.
CONCLUSION
Recent advances in neuroscience have fostered a shift in thinking as to how various clinical disorders and behaviors are mediated, with evidence pointing to subtle alterations across multiple brain regions, neurotransmitter systems and synaptic processes that converge as neural circuits. Although it is tempting to proceed with technological advances that allow us to examine and manipulate single cells, for neurodevelopmental disorders, a systems level approach is necessary and will be heavily relied upon for therapeutic development strategies. As the number of sophisticated tools increases, we must not forget that there is no replacement for behavioral and neuroanatomical outcomes, the clinically relevant tools that continue to drive translational research forward. For many of these complex behavioral assays outlined above, the ultimate goal is to identify disease-relevant endpoints that are robust, reliable and reproducible, and that can be employed to evaluate potential novel therapeutic agents. 
